Met Non Small Cell Cancer Registry (MOMENT)
ConditionCancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorEMD Serono Research & Development Institute, Inc.
About this trial
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Eligibility criteria
Qualifiers
Participants who signed ICF
Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
Participants who are starting or are already being treated with systemic therapy
Disqualifiers
Participants who are enrolled in a clinical trial
Trial design
Treatments tested in this trial
- Not listed
Trial groups
700 Participants
are grouped into 1 trial groupSponsors and collaborators
EMD Serono Research & Development Institute, Inc.
Lead sponsor
Merck KGaA, Darmstadt, Germany
Collaborator
Source ClinicalTrials.gov